DUGAN RICHARD W 4
4 · Vanda Pharmaceuticals Inc. · Filed May 29, 2020
Insider Transaction Report
Form 4
DUGAN RICHARD W
Director
Transactions
- Exercise/Conversion
Nonstatutory Stock Option (Right to Buy)
2020-05-28−15,000→ 0 totalExercise: $7.38Exp: 2020-06-02→ Common Stock (15,000 underlying) - Sale
Common Stock
2020-05-28$11.04/sh−10,129$111,806→ 40,641 total - Exercise/Conversion
Common Stock
2020-05-28$7.38/sh+15,000$110,700→ 50,770 total
Footnotes (3)
- [F1]Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire June 2, 2020 as reflected in this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.99 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vested in 12 equal monthly installments beginning on July 3, 2010.